BACKGROUND/AIM: The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated. PATIENTS AND METHODS: Between August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal Hospital. Risk factors for survival were examined by univariate and multivariate analyses. RESULTS: In 41 patients, mild neutropenia (grade 1-2) occurred in 10 patients (24.4%), severe neutropenia (grade 3-4) occurred in 13 (31.7%), and 18 (43.9%) did not experience neutropenia. The median overall survival times in the absent, mild, and severe groups were 120 days (95% confidence interval [CI], 67-179), 184 days (95% CI, 94-274), and 299 days (95% CI, 192-404), respectively (p = 0.045). In patients with severe neutropenia, the death hazard ratio was 0.442 (95% CI, 0.201-0.974; p = 0.042). CONCLUSION: In patients with advanced/recurrent colorectal cancer, TAS-102-induced severe neutropenia was associated with superior survival.
BACKGROUND/AIM: The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated. PATIENTS AND METHODS: Between August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal Hospital. Risk factors for survival were examined by univariate and multivariate analyses. RESULTS: In 41 patients, mild neutropenia (grade 1-2) occurred in 10 patients (24.4%), severe neutropenia (grade 3-4) occurred in 13 (31.7%), and 18 (43.9%) did not experience neutropenia. The median overall survival times in the absent, mild, and severe groups were 120 days (95% confidence interval [CI], 67-179), 184 days (95% CI, 94-274), and 299 days (95% CI, 192-404), respectively (p = 0.045). In patients with severe neutropenia, the death hazard ratio was 0.442 (95% CI, 0.201-0.974; p = 0.042). CONCLUSION: In patients with advanced/recurrent colorectal cancer, TAS-102-induced severe neutropenia was associated with superior survival.
Authors: A Fernandez Montes; F Vazquez Rivera; N Martinez Lago; M Covela Rúa; A Cousillas Castiñeiras; P Gonzalez Villarroel; J de la Cámara Gómez; J C Méndez Méndez; M Salgado Fernández; S Candamio Folgar; M Reboredo López; M Carmona Campos; E Gallardo Martín; M Jorge Fernández; M L Pellón Augusto; L París Bouzas; J García Gómez Journal: Clin Transl Oncol Date: 2019-05-09 Impact factor: 3.405
Authors: T Yoshino; J M Cleary; E Van Cutsem; R J Mayer; A Ohtsu; E Shinozaki; A Falcone; K Yamazaki; T Nishina; R Garcia-Carbonero; Y Komatsu; H Baba; G Argilés; A Tsuji; A Sobrero; K Yamaguchi; M Peeters; K Muro; A Zaniboni; N Sugimoto; Y Shimada; Y Tsuji; H S Hochster; T Moriwaki; B Tran; T Esaki; C Hamada; T Tanase; F Benedetti; L Makris; F Yamashita; H-J Lenz Journal: Ann Oncol Date: 2020-01 Impact factor: 32.976